The U.S. Food and Drug Administration (FDA) approved a supplemental application for Keytruda (pembrolizumab) on November 13, 2020. This approval, identified as BLA 125514 S-88, was specifically granted for efficacy, indicating an expansion of the drug's approved uses or patient population based on new clinical data.
Background
Pembrolizumab, marketed under the brand name Keytruda, is a well-established immunotherapy drug. It is sponsored by MERCK SHARP DOHME. This supplemental approval for efficacy further broadens its therapeutic profile. As an immune checkpoint inhibitor, pembrolizumab has been previously approved for various cancer indications, playing a significant role in oncology. This latest approval reinforces its demonstrated effectiveness across different settings.
What this means
This supplemental approval signifies that Keytruda (pembrolizumab) has demonstrated additional efficacy in a new indication or patient population, as thoroughly reviewed and determined by the FDA. The approval of BLA 125514 S-88 allows healthcare professionals to consider pembrolizumab for an expanded range of patients or conditions where its efficacy has now been officially recognized. This development provides new treatment options for patients who may benefit from pembrolizumab therapy, thereby broadening its clinical utility and impact in cancer care based on the latest evidence.
Source
The information regarding this supplemental approval was obtained from the official FDA database for drug approvals. The approval for BLA 125514 S-88, pertaining to Keytruda (pembrolizumab), was documented on November 13, 2020, and is publicly accessible on the accessdata.fda.gov website, maintained by the U.S. Food and Drug Administration.